公开(公告)号：US20220096472A1

公开(公告)日：2022-03-31

申请号：US17396187

申请日：2021-08-06

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US20210338673A1

公开(公告)日：2021-11-04

申请号：US17308486

申请日：2021-05-05

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. XIANG ,  Justin T. Ernst

IPC: A61K31/506 ,  C07D473/34 ,  C07D487/04 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US11083727B2

公开(公告)日：2021-08-10

申请号：US16233507

申请日：2018-12-27

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US11014926B2

公开(公告)日：2021-05-25

申请号：US16378809

申请日：2019-04-09

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E Webber

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20190330216A1

公开(公告)日：2019-10-31

申请号：US16378809

申请日：2019-04-09

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E Webber

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US09957277B2

公开(公告)日：2018-05-01

申请号：US15358761

申请日：2016-11-22

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan X. Xiang ,  Christian Nilewski ,  Theo Michels

IPC: C07D491/00 ,  C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

CPC classification number: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.